Clinigen Group plc Board Appointment (4009H)

TIDMCLIN

RNS Number : 4009H

Clinigen Group plc

15 November 2018

15 November 2018

Board Appointment

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceutical and services company, announces that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.

Alan is CEO of Boyd Consultants, a UK based consultancy to the pharmaceutical and biotechnology industry. He has over 30 years of sector experience, holding senior roles within Glaxo Group, ICI Pharma, Zeneca Pharmaceuticals and Ark Therapeutics. Alan is a graduate in Biochemistry and Medicine from the University of Birmingham and is currently a Fellow and immediate past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians. He is also a Fellow of the Royal College of Physicians, London and a Council Member of the Academy of Medical Royal Colleges.

Alan is currently working as a consultant for Clinigen providing clinical and regulatory consultancy services in relation to its medical products.

Peter Allen, Chairman of Clinigen, said:

"On behalf of the Board, we are delighted to welcome Alan to the Group. He brings extensive industry experience and expertise in pharmaceutical services. His appointment strengthens the Board and will help to support and deliver the Group's strategy. We are very much looking forward to working with Alan in his new NED capacity."

The following information is disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Professor Alan Keith Boyd, aged 63 years, is currently or has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships 
 
              *    The Faculty of Pharmaceutical Medicine of the Royal 
                   Colleges of Physicians, UK 
 
 
              *    BaxterBoyd Limited 
 
 
              *    Celentyx Limited 
 
 
              *    Alan Boyd Consultants Limited 
 
 
              *    Basildon Court Residents Company Limited 
 
 
 Past directorships (last 5 years) 
 
              *    Linear Diagnostics Limited 
 
 
              *    Alta Bioscience Limited 
 
 
              *    Bioscience Ventures Limited 
 
 
              *    The Academy Of Medical Royal Colleges 
 
 
              *    Genable Technologies Limited 
 

There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

Contact details

 
 Clinigen Group plc                             Tel: [phone] 
 Peter Allen, Chairman 
 Shaun Chilton, Group Chief Executive 
  Officer 
 Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited                       Tel: [phone] 
                                                 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
  James Black / Tom Ballard (Corporate 
  Broking) 
 
 RBC Capital Markets - Joint Broker             Tel: [phone] 
                                                 4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: [phone] 
                                                 2020 
 Melanie Toyne-Sewell / Alex Shaw / Deborah     Email: [e-mail] 
  Bell 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOADZLFFVFFZFBB

(END) Dow Jones Newswires

November 15, 2018 04:00 ET (09:00 GMT)